CurrentPartnering, Nov 2010, Pages: 324
The AssetPurchase Terms and Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter assetpurchase deals.
- Product
Global Industry Analysts, Inc., April 2011, Pages: 402
, which primarily comprises therapeutic drugs, vaccines, animal biologicals, insulin, diagnostics and statins, continues to account for the largest share in total revenues of the biotech industry
Global Industry Analysts, Inc., Oct 2010, Pages: 659
ELITech Takes Over Assets of Nanogen 82
LabCorp Signs Definitive Agreement with Monogram Biosciences 82
Axial Biotech and University of Utah Enter into Collaboration 82
Celera and Bayer Schering Pharma
CurrentPartnering, Nov 2010, Pages: 428
The Drug Delivery Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the drug delivery partnering agreements entered
Industry Experts, April 2010, Pages: 240
as the market share is growing gradually. In terms of market revenue, out of total pharma market the biopharmaceutical products were accounted for about 10% in 2006 and are projected to account for about 15% by 2015
Global Industry Analysts, Inc., Jan 2011, Pages: 354
Genetic Tests
USDA Purchases Fluidigm EP1 System
XDx and Bristol-Myers Squibb Company Signs Collaborative
Agreement
Commonwealth Biotechnologies Divests Assets of Bioanalytical
and Genetic Testing
CurrentPartnering, June 2009, Pages: 471
The Oncology Partnering Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the oncology partnering agreements entered
Global Industry Analysts, Inc., Jan 2011, Pages: 917
Technologies
Growing Collaboration between Biotech and Pharma Companies
5. PRODUCT OVERVIEW
A. Classification
i. DNA Synthesis & Sequencing Reagents
DNA: The Basis for Modern Biotechnology
ii. PCR
CurrentPartnering, Feb 2012
to the industry focus of each of the parties to the deal using the following categories:
- Bigpharma
- Pharmaceuticals
- Biotech
- Diagnostics
- Drug delivery
- Medical devices
- Consumer health
- Specialty pharma
Global Industry Analysts, Inc., Oct 2010, Pages: 446
66
Origin Biotechnology Enters into Agreement with Sichuan
Biotech and CAS 66
Dow AgroSciences and NemGenix Form Collaboration
CurrentPartnering, Jan 2011, Pages +: 1100
The Partnering and M&A Deals in Pharma and Biotech Yearbook 2010 report provides comprehensive understanding and unprecedented access to the partnering and M&A deals and agreements entered
Global Industry Analysts, Inc., Feb 2011, Pages: 630
and Biotech Companies 19
Tech Giants Join the Biochip Fray 20
5. PRODUCT OVERVIEW 21
Biochips - Complex Blend of Biochemistry and Electronics 21
Historical Perspective 21
Lab-on-a-chip: An Enabled
Global Industry Analysts, Inc., Jan 2011, Pages: 437
Merges with Home Diagnostics 67
PositiveID PurchasesAssets and Intellectual Property Rights
of Easy Check 67
Global Industry Analysts, Inc., Oct 2011, Pages: 446
Meter Deal with Medtronic 77
Roche & LifeScan Bag Supply Contract from Premier Purchasing
Partners 78
Bio Pharmetics Inks an Agreement with HMD 78
Arkray Acquires Hypoguard 78
Home Diagnostics
Global Industry Analysts, Inc., Oct 2010, Pages: 278
Imaging System 40
NNSA Chooses GEH for Supply of Molybdenum-99 41
Digirad Inks AssetPurchaseAgreement with MD Office Solutions 41
Siemens
Global Industry Analysts, Inc., Oct 2010, Pages: 2423
Buys NanoProductsAssets & Intellectual Property 169
Bayer Group Inks Agreement with Toyota Tsusho 169
First Nano Supplies ET3000-BN to Brookhaven National
CurrentPartnering, Jan 2012, Pages +: 5000
7.4. By deal type
Asset and productpurchase
Assignment
Bigpharma out-licensing
Collaborative R&D
Co-development
Co-marketing
Co-promotion
Contract service
CRADA
Cross-licensing
Development
Distribution
Global Industry Analysts, Inc., Jan 2011, Pages: 789
This report analyzes the worldwide markets for Bioinformatics in US$ Million by following Product segments: Software, Hardware, and Biocontent. The report provides separate comprehensive analytics
Global Industry Analysts, Inc., Oct 2010, Pages: 565
® 100
Inspire and Santen Secure Japanese Approval for DIQUAS 100
Asahi Kasei Pharma and Altheos Enter into License Agreement 100
OPKO Health Takes Over
CurrentPartnering, Jan 2012, Pages +: 4000
of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
6.4. By deal type
Asset and productpurchase
Assignment
Bigpharma out-licensing
Collaborative R&D
Co-development
Co-marketing
